200,000+ products from a single source!
sales@angenechem.com
273-99-4 | Thiazolo[4,5-d]pyrimidine (8CI,9CI)
CAS No: 273-99-4 Catalog No: AG00BUZL MDL No:
Product Description
Catalog Number:
AG00BUZL
Chemical Name:
Thiazolo[4,5-d]pyrimidine (8CI,9CI)
CAS Number:
273-99-4
IUPAC Name:
[1,3]thiazolo[4,5-d]pyrimidine
InChI:
InChI=1S/C5H3N3S/c1-4-5(7-2-6-1)8-3-9-4/h1-3H
InChI Key:
YWBULOYFCXZCGF-UHFFFAOYSA-N
Properties
Complexity:
108
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
137.005g/mol
Formal Charge:
0
Heavy Atom Count:
9
Hydrogen Bond Acceptor Count:
4
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
137.16g/mol
Monoisotopic Mass:
137.005g/mol
Rotatable Bond Count:
0
Topological Polar Surface Area:
66.9A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1
Literature
| Title | Journal |
|---|---|
| Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives. | Bioorganic & medicinal chemistry 20120915 |
| Discovery and development of thiazolo[3,2-a]pyrimidinone derivatives as general inhibitors of Bcl-2 family proteins. | ChemMedChem 20110502 |
| Synthesis of thiazolo[4,5-d]pyrimidine derivatives as potential antimicrobial agents. | Archives of pharmacal research 20071201 |
| 2'-Deoxyimmunosine: a thiazolo[4,5-d]pyrimidine nucleoside adopting the syn conformation. | Acta crystallographica. Section C, Crystal structure communications 20070901 |
| SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction. | Bioorganic & medicinal chemistry letters 20070515 |
| Synthesis and antitumor evaluation of new polysubstituted thiazole and derived thiazolo[4, 5-d]pyrimidine systems. | Archiv der Pharmazie 20020501 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.